

September 10, 2010

**ONO PHARMACEUTICAL Co., LTD.**

President and Representative Director: Gyo Sagara,  
Code No.: 4528 at the 1<sup>st</sup> section of the Tokyo / Osaka Stock Exchange  
INQUIRIES: Kinya Morimoto, Managing Director, Corporate Communications

**ASTELLAS PHARMA INC.**

President and CEO: Masafumi Nogimori  
Code No.: 4503 at the 1<sup>st</sup> section of the Tokyo / Osaka Stock Exchange  
INQUIRIES: Makoto Kawamura, Director, Corporate Communications

**Application for RECALBON<sup>®</sup> Tablets 50mg/ Bonoteo<sup>®</sup> Tablets 50mg,  
A Monthly Oral Osteoporosis Treatment in Japan**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) and Astellas Pharma Inc. (Tokyo, Japan) announced the submission of a market authorization application for RECALBON<sup>®</sup> Tablets 50mg (Ono) / Bonoteo<sup>®</sup> Tablets 50mg (Astellas) (generic name: minodronic acid hydrate) to Pharmaceuticals and Medical Devices Agency today in Japan.

Minodronic acid hydrate is an oral bisphosphonate that has been discovered by Astellas and has been co-developed by Ono and Astellas. This drug increases the bone mineral density and the strength by inhibiting osteoclastic bone resorption. RECALBON<sup>®</sup> Tablets 1mg / Bonoteo<sup>®</sup> Tablets 1mg, a daily formulation of this drug, demonstrated a significant efficacy in bone fractures prevention, and launched in April, 2009 in Japan.

In a Phase 2 / 3 study in Japan, RECALBON<sup>®</sup> Tablets 50mg / Bonoteo<sup>®</sup> Tablets 50mg, a monthly formulation of this drug, demonstrated non-inferiority to the daily formulation 1 mg in average bone mineral density change in lumbar spines, the primary endpoint. Furthermore, in the safety evaluation of the Phase 2 / 3 study, monthly formulation 50 mg appeared to be safe, and the incidence of side-effects was low and comparable to the daily formulation 1 mg. Based on the results of the study, RECALBON<sup>®</sup> Tablets 50mg / Bonoteo<sup>®</sup> Tablets 50mg is expected to have an equivalent effect in bone fractures prevention to the daily formulation and to boost the patients' convenience by reducing the dose frequency.

Since the launch of RECALBON<sup>®</sup> Tablets 1mg / Bonoteo<sup>®</sup> Tablets 1mg in Japan, Ono and Astellas have contributed to the improvement of the quality of life of the patients suffering from osteoporosis through the prevention of bone fractures. The both companies expect that RECALBON<sup>®</sup> Tablets 50mg / Bonoteo<sup>®</sup> Tablets 50mg, if approved, will provide a new therapeutic option to the current osteoporosis treatment in addition to RECALBON<sup>®</sup> Tablets 1mg / Bonoteo<sup>®</sup> Tablets 1mg, and believe to contribute further to the patients.